Evaluation of neutrophil phagocytic, complement functions, and cytokines expression among diabetic patients in Abuja, Nigeria

Authors

  • Babandina Muhammad Musa Department of Medical Laboratory Services, University of Abuja Teaching Hospital Gwagwalada, FCT Abuja, Nigeria https://orcid.org/0000-0003-4090-1092
  • Abdullahi Suleiman Mainasara Department of Chemical Pathology, School of Medical Laboratory Sciences, Usmanu Danfodiyo University Sokoto, Sokoto, Nigeria
  • Mustapha Bakare Department of Medical Laboratory Services, University of Abuja Teaching Hospital Gwagwalada, FCT Abuja, Nigeria
  • Anthony Uchenna Emeribe Department of Medical Laboratory Science, University of Calabar, Calabar, Nigeria https://orcid.org/0000-0003-2937-8595
  • Halima Ali Shuwa Department of Community Health, Federal University Dutse, Jigawa, Nigeria https://orcid.org/0000-0002-7926-0360
  • Shamsuddeen Haruna Department of Medical Laboratory Science, Ahmadu Bello University, Zaria, Nigeria https://orcid.org/0000-0002-8991-6685
  • Aminu Said Muhammad Department of Medicine, National Hospital, Abuja, Nigeria
  • Idris Nasir Abdullahi Department of Medical Laboratory Science, Ahmadu Bello University, Zaria, Nigeria https://orcid.org/0000-0002-5511-1272

DOI:

https://doi.org/10.15584/ejcem.2019.3.5

Keywords:

diabetes mellitus, effector molecules, pro-inflammatory markers

Abstract

Introduction. Inflammatory response in Diabetes Mellitus (DM) begins with chronic sub-clinical inflammations as a result of insulin resistance and activation of both innate and adaptive immune system as the disease progresses to complicated diabetes. Hence, the present study investigated the neutrophil phagocytic, complement function (CH50), and some cytokine profiles among diabetic and non-diabetic patients attending the National Hospital in Abuja, Nigeria.

Aim. To evaluate the neutrophil phagocytic, complement function (CH50), and some cytokine profiles among post-operative septic diabetic and post-operative septic non-diabetic patients at the National Hospital in Abuja, Nigeria.

Material and methods. Subjects were recruited by convenient sampling technique through interviewer-administered questionnaires. Subsequently, blood samples were collected. Fasting blood sugar (FBS) (mmol/L) was determined using glucose oxidase method. Neutrophil function test (Fmol/phag) was assayed using nitroblue tetrazolium reduction test (NBT). Hemolytic complement function (CH 50) test was conducted using serum harvested from sheep sensitized with human group (ORh D +ve) red blood cells. While serum Interleukin-4, -6, -10 and TNF- α were determined using Enzyme Linked Immunosorbent Assay (ELISA).

Results. Mean ± Standard deviation (SD) of FBS concentration of 10.5 ± 1.3 (mmol/|L) among diabetic and 4.7 ± 0.9 (mmol/L) among non-diabetics was recorded. There is a decrease in neutrophil phagocytic function with a mean ± SD of 5.4 ± 2.1 (Fmol/ phag) in diabetics compared to 9.2 ± 2.1 (Fmol/phag) in non-diabetics. Similarly, complement (CH 50) function and C-reactive protein were significantly lower in diabetics when compared to non-diabetics (p<0.001). There was a significant difference in IL-6 concentration between diabetics and non-diabetics groups, but no significant difference was observed in TNF-α, IL-4 and IL-10 concentrations between study groups (p>0.05). TNF-α and IL-6 was significantly higher in diabetics with cardiovascular disorders compared to non-diabetics subjects with cardiovascular disorders (p<0.001).

Conclusion. Findings from this study revealed the association of complement, neutrophil phagocytic function, CRP and IL-6 among septic diabetic patients,. In addition TNF-α and IL-6 expression was higher in DM patients with cardiovascular disorders. 

Downloads

Download data is not yet available.

References

World Health Organization, Global Report on Diabetes. Geneva, 2016.

Fasil TA, Ayo D, Hanxia H. Genome-wide associated loci influencing interleukin (IL)-10, IL-1Ra, and IL-6 levels in African Americans. Immunogenetics. 2011;41-60.

Nagham J, Hawa E, Kenneth N. The effect of short-term hyperglycaemia on the innate immune system. Am J Med Sci. 2016;351(2):201-211.

Dwijo A, Sindhughosa AA, Gde-Marvy KP. The involvement of pro-inflammatory cytokines in diabetic nephropathy: Focus on interleukin 1 (IL-1), interleukin 6 (IL-6) and tumour necrotic factor-alpha (TNF-A) signalling mechanism. Bali Med J. 2017;6(1);44 – 51.

Al-Lamki RS, Mayadas TN. TNF receptors: signaling pathways and contribution to renal dysfunction. Kidney Int J. 2017;87(2):281–296.

Elahe M, Maryam A, Seyed RM, et al. Relationship between serum pro- and anti-inflammatory cytokine and growth factor concentrations with the age and gender adjusted prevalence of diabetes and pre-diabetes. Int J Diabn Dev Countr. 2016;34(5):231–238.

American Diabetes Association (ADA). Economic costs of diabetes in the U.S. in 2012.Journal of Diabetes Care. 2014;36(4):1033–1046.

Laily N, Mojtaba M, Ameneh EV, Mohammad EK. Acute phase proteins and diabetes microvascular complications. Int J Diabetes Dev Countr. 2015;25(5):504-514.

Yong-chao Q, Jian S, Lan H, et al. Changes of Regulatory T Cells and of Proinflammatory and Immunosuppressive Cytokines in Patients with Type 2 Diabetes Mellitus: A Systematic Meta-Analysis. J Diabetes Res. 2016;20(6):1-19.

Kristianse OP, Mandrup- Paulson T. Interleukin-6 and Diabetes: The Good, the Bad, or the Indifferent? Diabetes. 2005;54(2):114-124.

Wolford JK, Colligan PB, Gruber JD, Bogardus C. Variants in the interleukin 6 receptor gene are associated with obesity in Pima Indians. Molecular Genetics and Metabolism. 2003;80:338-343.

Aslan D. Biomarkers for Diabetes Complications: The Results of Several Clinical Studies. Journal of Medical Biochemistry. 2011;30(3):207-212.

Chenxiao L, Xianjin K, Ying W, et al. The level of netrin-1 is decreased in newly diagnosed type 2 diabetes mellitus patients. BMC Endocrine Disorders. 2016;16(4):122-131.

Arababadi MK, Reza Mirzaei M, Ali Sajadi SM, et al. Interleukin (IL)-10 gene polymorphisms are associated with type 2 diabetes with and without nephropathy: a study of patients from the southeast region of Iran. Inflammation. 2012;35(3):797-802.

Sanjabi S, Zenewicz LA, Kamanaka M, Flavell RA. Anti-inflammatory and pro-inflammatory roles of TGF-beta, IL-10, and IL-22 in immunity and autoimmunity. Current Opinion in Pharmacology. 2009;9:447–453.

Onyenekwe CC, Ukibe NR, Ahaneku JE, et al. use of Absolute Lymphocyte Count or Neutrophil Ingestion Rate of NitroblueTetrazolium (NBT) as Alternative Index to CD4+T cell Count to Initiate ART Management of HIV/AIDS Disease, International Journal of Biochemical Sciences. 2012;6(1):99-107.

Kim SH, Park KW, Kim YS. Effects of acute hyperglycaemia on endothelium-dependent vasodilation in patients with diabetes mellitus or impaired glucose metabolism. The American Journal of the Medical Science. 2016;35(10):65–70.

Oni AA, Ewete AF, Gbaja A, Tkolade AF, Mutiu WB, Adeyemo DA. Increased Recruitment but Impaired Function of Leukocytes during infection: Surgical site infection in UCH Ibadan, Inflammation in Mouse Models of Type 1 and Type 2 Diabetes Nigeria. Journal of Surgery and Research. 2013;17(5):45–51.

Chenxiao L, Xianjin K, Ying W, et al. The level of netrin-1 is decreased in newly diagnosed type 2 diabetes mellitus patients. BMC Endocrine Disorders. 2016;16(4):122-131.

Anelise MB, Breno FM, de Almeida M, Priscila PP, Luis GN. High concentrations of glucose reduce the oxidative metabolism of dog neutrophils in vitro. Journal of biomed centre. 2013;9(2):143-149.

Harshad K, Koch K, Jeitler K, Matyas E, Bender R, Bastian H. Effects of treatment in women with gestational diabetes mellitus: systematic review and meta-analysis. British Medical Journal. 2010;34(10):1395-1399.

Judith AO, Jenni P, Sharon AS, Patricia PJ. Kuby Immunology. Seventh edition: 2013;345-353.

Juan F, Naverro G, Carman MF. The role of inflammatory cytokines in diabetic nephropathy. Journal of American Society for Nephrologists. 2008;19(3):433–442.

Joachim S, Anja K, Matthias M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes. Diabetes Journal. 2013;52(4):812- 817.

Marisa CB, Guilherme AT, Tharsus DT, et al. Immunological evaluation of patients with type 2 diabetes mellitus submitted to metabolic surgery. J immunol. 2015;23(5):231-236.

Zaid AM, Ali A, Riyadh S. Association of adipokines, leptin/adiponectin ratio and C-reactive protein with obesity and type 2 diabetes mellitus. Diabetology & Metabolic Syndrome. 2014;6(1):99 –104.

Cathy C, Lee MS, Simin L. Role of inflammatory cytokines in type 2 diabetes Journal of Endocrinol. 2008;14(5);19–24.

Youn-Hee C, Robert E, McKeown EJ, et al. Serum C-Reactive Protein and Immunoglobulin G Antibodies to Periodontal Pathogens May Be Effect Modifiers of Periodontitis and Hyperglycaemia. Journal of Periodontology. 2014;85 (9):1172-1181.

Ahn JH, Yu JH, Ko SH, Kim JH. Prevalence and determination of diabetes nephropathy in Korea: Korea National Health and Nutrition Examination Survey. Journal of Diabetes and Metabolism. 2014;38(9):109–119.

Kiykim A, Turgutalp K, Bardak S, Özcan T, Derici D. Red Blood Cell Distribution Width Level: A Predictive Marker for Early Detection and Monitoring of Diabetic Nephropathy Progression. European Journal of Inflammation. 2014;12(1):109-116.

Weijiang F, Wenhang W, Lan Z, Lihong Q, Anjun L. Study on changes and mechanisms of cytokines for alloxan-induced hepatic injury by Cr3+-treatment in mice. Molecular & Cellular Toxicology. 2006;12(2):209-216.

Kolseth IB, Reine TM, Parker K, et al. Increased levels of inflammatory mediators and proinflammatory monocytes in patients with type I diabetes mellitus and nephropathy. Journal of Diabetes and its Complications. 2017;31(1):245-252.

Downloads

Published

2019-09-30

How to Cite

Muhammad Musa, B., Mainasara, A. S., Bakare, M., Emeribe, A. U., Shuwa, H. A., Haruna, S., Muhammad, A. S., & Abdullahi, I. N. (2019). Evaluation of neutrophil phagocytic, complement functions, and cytokines expression among diabetic patients in Abuja, Nigeria. European Journal of Clinical and Experimental Medicine, 17(3), 229–235. https://doi.org/10.15584/ejcem.2019.3.5

Issue

Vol. 17 No. 3 (2019)

Section

ORIGINAL PAPERS

License

Copyright (c) 2019 European Journal of Clinical and Experimental Medicine

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.

All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.